StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

STLN — Starling Oncology, Inc.

EXPENSIVE (MOS -10.1%) · Quality 55/100

Price
6.96
Intrinsic value
6.32
Margin of safety
-10.1%
Implied growth (reverse DCF)
+21.3%
model assumes +20.0%
Value Score
8.8
Quality
55
Psychology
-48.2
Discovery
34.7
price/volume attention only
Moat score
21
erosion: none

Value Score: bottom 12% of Russell 3000 · Quality: top 46%

Open the interactive Deep Dive for STLN →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/STLN - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is STLN undervalued?

As of 2026-09-19, STLN trades at 6.96 against a computed intrinsic value of 6.32 (-10.1% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is Starling Oncology, Inc.'s Value Score?

Starling Oncology, Inc.'s Value Score is 8.8 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.